Denmark-based Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised the first options under an existing contract to supply a freeze-dried version of the JYNNEOS smallpox vaccine.
The first doses of this vaccine version will be manufactured and invoiced in 2023 and 2024.
“Denmark-based Bavarian Nordic A/S announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised the first options under an existing contract to supply a freeze-dried version of the JYNNEOS® smallpox vaccine.” https://t.co/djmxL3W1Qu
— My2pups1🐭🦝🐔 (@My2pets1) May 19, 2022
From Precision Vaccinations:
If exercised, additional options on the BARDA contract support the conversion of up to a total of approximately 13 million freeze-dried doses of JYNNEOS smallpox vaccine that are expected to be manufactured in 2024 and 2025.
The majority of the bulk vaccine for these doses has already been manufactured.
A supplement to the existing liquid frozen JYNNEOS U.S. FDA BLA will be made comprising Phase 3 clinical study data, which has already been completed and reported, together with the manufacturing data to support the approval of the freeze-dried version of JYNNEOS in 2024.
Paul Chaplin, President and CEO of Bavarian Nordic, commented in today’s press release, “We are pleased to announce the exercise of the first options under our contract with the U.S. government to deliver a freeze-dried version of the smallpox vaccine with an improved shelf-life, which will be manufactured at our new fill and finish facility.”
“This marks a significant milestone in our long-standing partnership with the U.S. government to ensure availability of life-saving vaccines for the entire population.”
Jynneos is based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the human body yet able to elicit a potent immune response.
To protect people from monkeypox, the Jynneos vaccine was approved by the U.S. FDA in 2019.
Bavarian Nordic A/S received $100 million from Fauci for research on a smallpox vaccine in preparation for a BioShield contract to be awarded in 2006.
From a 2009 KHN report:
In another instance, Fauci gave about $100 million each to Bavarian Nordic and Acambis for research on a smallpox vaccine in preparation for a BioShield contract to be awarded in 2006. NIH officials gave Acambis samples of the modified smallpox virus used by Bavarian, prompting Bavarian to file a civil lawsuit and a patent complaint against Acambis. Bavarian did not sue NIH, however, and Acambis maintains that it received the virus without restrictions on its use, the Journal reports. Fauci could not comment on the case.
That entire article is worth a read for more info on Fauci’s efforts to “direct funding to drug companies to produce biodefense medicines.”